# waveLINE-003

Source: https://onco.cc/trials/waveline-003/  
OnCo record `waveline-003` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

waveLINE-003 tests a ROR1-directed ADC added to standard salvage chemotherapy.

## Summary

waveLINE-003, trial NCT05139017 sponsored by Merck, is a phase 2/3 trial testing the ROR1-directed antibody-drug conjugate zilovertamab vedotin, also known as MK-2140, added to rituximab, gemcitabine and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma after at least one line, in transplant-ineligible or post-transplant patients. A companion frontline trial, waveLINE-010, tests the drug with R-CHP. OnCo links it to lymphoma, ROR1 as a target and zilovertamab vedotin. It is recruiting with no results, and whether ROR1, a target without an approved drug, can be exploited safely with an ADC is the question it exists to answer.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-07
- Registry id: NCT05139017
- Phase: 2/3
- Setting: R/R DLBCL after ≥1 line: zilovertamab vedotin + R-GemOx vs R-GemOx
- Sponsor: Merck

## Sources

- ClinicalTrials.gov NCT05139017: https://clinicaltrials.gov/study/NCT05139017

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [ROR1](https://onco.cc/targets/ror1/)
- drugs: [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/waveline-003.json